Class | Brand | Generic | Indication | Dose Form | Route | Adult Dose | Ped. Dose | MOA |
Antianxiety; Benzodiazepine (Short or Intermediate Acting) | Xanax | Alprazolam | Anxiety; panic disorder | Oral Tablet:
0.25, 0.5, 1, 2mg; ODT:
0.25, 0.5, 1, 2;
ER Tablet:
0.5, 1, 2, 3mg;
Oral Soln:
1mg/ml | Oral | Anxiety:0.25-0.5 tid
Panic disorder: 0.5 tid
max: 10mg/day | N/A | Possibly binds to various stereo-specific receptors in the CNS |
Benzodiazepine (Short-Intermediate Acting); Hypnotic | Restoril | Temazepam | Insomnia | Oral Capsule:
7.5, 15, 22.5, 30mg | Oral | 7.5-30mg at bedtime | N/A | Hypnotic agent belonging to the benzodiazepine class |
Antidiabetic; Ultra Rapid Acting Insulin | NovoLog; NovoLog Flexpen | Insulin Aspart (70/30) | Type 1&2 DM | SubQ Susp/Soln: 100U/ml
(10ml vials)
(3ml flexpen) | SubQ | Inject dose 5-10 minutes before a meal; dose varies | 2YO+
Inject dose
5-10 minutes before a meal; dose varies | Binds to insulin receptors on muscle and fat cells allowing for increased cellular uptake of glucose and subsequent decreases in blood glucose |
Antidiabetic; Ultra Rapid Acting Insulin | Humalog; Humalog Kwikpen | Insulin Lispro | Type 1&2 DM | SubQ Susp/Soln: 100U/ml
(10ml vials)
(3ml kwik-pen) | SubQ | Inject dose 5-10 minutes before a meal; dose varies | 3YO+
Inject dose
5-10 minutes before a meal; dose varies | Binds to insulin receptors on muscle and fat cells allowing for increased cellular uptake of glucose and subsequent decreases in blood glucose |
Antidiabetic;
(R) Rapid Acting and (N) Intermediate Acting | Humulin N; Humulin R | Insulin | Type 1&2 DM | (N)Susp:100U/ml
(R) soln: 100U/mL, 500U/mL | SubQ | dosages need to be individualized
Type 1: 0.5-0.6 U/kg/day up to 3x /day
Type2: 0.2-0.6 U/kg/day | 12 yo and older :same as adults | Binds to insulin receptors on muscle and fat cells allowing for increased cellular uptake of glucose and subsequent decreases in blood glucose |
Antidiabetic; Long Acting Insulin | Lantus; Lantus Solostar | Insulin Glargine | Type 1&2 DM | SubQ Soln: 100U/ml
Pen-Injector | SubQ | Individualized dosing for once daily (same time each day) | 6YO+ individualized dosing | Binds to insulin receptors on muscle and fat cells allowing for increased cellular uptake of glucose and subsequent decreases in blood glucose |
Antidiabetic; Long Acting Insulin | levemir | Insulin Detemir | Type 1&2 DM | SubQ Soln: 100U/ml
Pen-Injector | SubQ | Individualized dosing QD-BID | 2YO+ individualized dosing | Binds to insulin receptors on muscle and fat cells allowing for increased cellular uptake of glucose and subsequent decreases in blood glucose |
Antidiabetic; Dipeptidyl Peptidase IV Inhibitor | Januvia; Janumet | Sitagliptin
Sitagliptin/
Metformin | Type 2 DM | Oral Tablet:
Januvia:25, 50, 100mg
Janumet:50/500,50mg/1000mg
Janumet XR: 50/500,50/1000,100mg/1000mg | Oral | 100mg QD with or without food | N/A | DPP-4 inhibitor
=increase insulin and decrease glucagon |
Antidiabetic; GLP-1 Receptor Agonist | Victoza | Liraglutide | Type 2 DM | SubQ Soln:
6mg/ml
Pen-Injector | SubQ | 0.6-1.2mg QD, may increase to 1.8mg QD | N/A | GLP-1 receptor agonist that acts to increase insulin release in the presence of elevated glucose concentrations, decrease glucagon secretion in a glucose-dependent manner, and delay gastric emptying |
Antidiabetic; GLP-1 Receptor Agonist | Byetta, Bydureon | Exenatide | Type 2 DM | SubQ Soln:
(pen-injector)
5mcg/0.2ml
10mcg/0.4ml | SubQ | IR: initial = 5mcg BID within 60mins before AM & PM meal (approx. 6 hrs apart);
Maintenance:
may increase to 10mcg BID | N/A | Acts as an incretin mimetic agent to enhance glucose-dependent insulin secretion |
Antidiabetic; Thiazo-lidinedione | Actos | Pioglitazone | Type 2 DM | Oral Tablet:
15, 30, 45mg | Oral | Initial = 15-30mg QD; max of 45mg QD | N/A | Thiazolidinedione antidiabetic agent & PPARĪ³ agonist, is dependent on the presence of insulin for its MOA |
Biguanide; Hypoglycemic | Glucophage; Riomet; Fortamet; | Metformin; | Type 2 DM | Oral Tablet:
500, 850, 1000mg; ER Tablet:
500, 750, 1000mg; Oral Soln(Riomet): 500mg/5ml | Oral | Type 2: IR: 500 BID-850 QD.Max: 2550mg/day
ER: 1000 QD.max: 2000mg/day | >10 yo:
IR: same as adults
ER: n/a | Lowers both basal and postprandial glucose levels in type 2 DM pts through several mechanisms: decreases hepatic glucose production, decrease intestinal absorption, and increases peripheral glucose uptake & utilization by improving insulin sensitivity |
Biguanide; Hypoglycemic; 2nd gen. sulfonylurea | Glucovance | Metformin/Glyburide | Type 2 DM | Oral Tablet:
Gly/Met
1.25mg/250mg
2.5mg/500mg
5.0mg/500mg | Oral | 1.25/250 bid
Max: 10mg/2000mg | N/A | Metformin MOA + Glyburide stimulates pancreatic beta cells to produce insulin. |
Amphetamine, CNS Agent/
Stimulant | Adderall; Adderall XR | Amphetamine Salts | ADHD; narcolepsy | ER Capsule:
5, 10, 15, 20, 25, 30mg;
IR Tablet:
5, 7.5, 10, 12.5, 15, 20, 30mg | Oral | ADHD:
20mg ER cap QD;
5mg IR tab QD-BID
Narcolepsy:
5-60mg IR tab QD or divided doses | 3YO+
dose varies based on age | Noncatechol sympathetic amine with CNS stimulant activity; purported to block the reuptake of NE and dopamine into the presynaptic neuron & increase their release into the extraneuronal space |
Amphetamine Related;
CNS Agent/
Stimulant | Concerta; Daytrana; Ritalin; Metadate; Methylin | Methylphenidate | ADHD; narcolepsy | Metadate:ER-C:
10,20,30,40,50,60mg; ER-T:20mg.
Ritalin:T:
5,10,20mg; ER-T:10,20,30,40
Concerta:ER Tab:
10,18,20,27,36,54mg
Methylin:Chew T:
2.5,5,10mg;Soln:5mg, 10mg/5mL
Patch(Daytrana):
10,
15 20,30mg/9hr | Oral, Topical | Varies
usually QAM
Max: 60mg/day | 6YO+
Dose varies
(Patch may be used on ped.) | Blocks the reuptake of NE and dopamine into the presynaptic neuron, thus increasing the concentrations of these monoamines in the extraneuronal space |
Amphetamine Related;
CNS Stimulant | Focalin XR | Dexmethylphenidate | ADHD | ER Capsule(XR):
5, 10, 15, 20, 25, 30, 35, 40mg;
IR Tablet(Focalin):
2.5, 5, 10 | Oral | Initial = 10mg QAM, adjust dose weekly in 10mg increments (max of 40mg/day) | 6YO+
ER, initial: 5mg QAM, adjust weekly in 5mg inc. Max ER: 30mg/day
Max IR:
20mg/day | Thought to block the reuptake of NE and DA into the presynaptic neuron, increasing the concentrations of these monoamines in the extraneuronal space |
Amphetamine; CNS Stimulant | Vyvanse | Lisdexamfetamine Dimesylate | ADHD,
Binge eating disorder | Oral Capsule:
10, 20, 30, 40, 50, 60, 70mg | Oral | Initial: 30mg QAM, may increase by increments of 10 or 20mg per day at approx. 1 week intervals
Max: 70mg/day | 6YO+
same dosing as adults | May block the reuptake of NE and DA |
Antianxiety; Anticonvulsant; Benzodiazepine (Short or Intermediate Acting) | Klonopin | Clonazepam | Panic disorder; Seizure | Oral Tablet:
0.5, 1, 2mg;
ODT:
0.125, 0.25, 0.5, 1, 2mg | Oral | 0.5 bid-tid.Max: 4mg/day | seizure:
>10yo: 0.5 tid
<10yo: 0.01-0.03 bid-tid | Believed to enhance GABA activity |
Antianxiety; Anticonvulsant; Benzodiazepine (Long Acting) | Valium | Diazepam | Alcohol withdrawal syndrome; anxiety; sedation; seizure; skeletal muscle spasm; status epilepticus | Inj. Soln:
5mg/ml;
Oral concentrate: 5mg/ml;
Oral Tablet:
2, 5, 10mg;
Rectal Gel: Diastat AcuDial: :10, 20mg. Diastat Pediatric: 2.5mg
IM device: 10mg/2mL | Oral, injection, IM, Rectal | 2-10mg bid-qid | > 6mo:
1-2.5 mg tid-qid | Reduces neuronal depolarization resulting in decreased action potentials. Enhances action of GABA by tightly binding to GABA-A receptors |
Antianxiety; Benzodiazepine (Short or Intermediate Acting) | Ativan | Lorazepam | Anxiety; insomnia; premedication for anesthetic procedure; status epilepticus | Inj. Soln:
2mg/ml, 4mg/ml; Oral concentrate:
2mg/ml; Oral Tablet:
0.5, 1, 2mg | Oral, Injection | anxiety:
1-2 mg bid-tid
insomnia: 2-4 mg QHS | 12YO+
dose varies | Binds highly to the GABA-BZ receptor complex without displacing GABA |